Skip Navigation


Hum. Reprod. Advance Access originally published online on March 26, 2008
Human Reproduction 2008 23(6):1338-1345; doi:10.1093/humrep/den091
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow Supplementary Data
Right arrow All Versions of this Article:
23/6/1338    most recent
den091v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mavranezouli, I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mavranezouli, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline

I. Mavranezouli on behalf of the LARC Guideline Development Group1

National Collaborating Centre for Women's and Children's Health (NCC-WCH), Royal College of Obstetricians and Gynaecologists, London, UK

1 Correspondence address. National Collaborating Centre for Mental Health (NCC-MH), Centre for Outcomes Research and Effectiveness Sub department of Clinical Health Psychology, University College London, 1–19 Torrington Place, London WC1E 7HB, UK. Tel: +44-207-679-1979; Fax: +44-207-91-68-511; E-mail: i.mavranezouli{at}ucl.ac.uk

BACKGROUND: Long-acting reversible contraceptive (LARC) methods are highly effective in preventing unintended pregnancies. However, their uptake is low in much of the developed world. This study aimed at assessing the cost-effectiveness of LARC methods from the British National Health Service (NHS) perspective.

METHODS: A decision-analytic model was constructed to estimate the relative cost-effectiveness of the copper intrauterine device (IUD), the levonorgestrel intrauterine system (LNG-IUS), the etonogestrel subdermal implant and the depot medroxyprogesterone acetate injection (DMPA). Comparisons with the combined oral contraceptive pill (COC) and female sterilization were also performed. Effectiveness data were derived from a systematic literature review. Costs were based on UK national sources and expert opinion.

RESULTS: LARC methods dominated COC (i.e. they were more effective and less costly). Female sterilization dominated LARC methods beyond 5 years of contraceptive protection. DMPA and LNG-IUS were the least cost-effective LARC methods. The incremental cost-effectiveness ratio of implant (most effective LARC method) versus IUD (cheapest LARC method) was £13 206 per unintended pregnancy averted for 1 year of use and decreased until implant dominated IUD in 15 years. Discontinuation was a key determinant of the cost-effectiveness of LARC methods.

CONCLUSIONS: LARC methods are cost-effective from the British NHS perspective. Practices improving user satisfaction and continuation of LARC method use should be identified and promoted.

Key words: long-acting reversible contraception/cost-effectiveness/discontinuation/economic modelling

Submitted on December 5, 2007; resubmitted on February 14, 2008; accepted on February 29, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.